During the last years, the diagnosis, management, and treatment of the ccRCC subtype have seen improvements resulting from various randomized and prospective phase III clinical trials including immunotherapy, which acts on immune checkpoints such as PD-1, CTLA-4, and PD-L1 (Javelin 101, CheckMate 9ER, Keynote 426, CheckMate 214, and CLEAR) (20–26). This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.